Latest Options News

Dalaroo Metals has secured 100% ownership of four gold permits in Côte d’Ivoire, leveraging extensive historical exploration data and planning aggressive drilling to unlock value in a prolific West African gold region.

Skin Elements Limited has locked in $2.5 million through a two-tranche placement to accelerate the commercial rollout of its SE Formula biotechnology products, offering investors discounted shares and options.

Green Critical Minerals is set to issue over 107 million shortfall shares to underwriters following the expiry of its quoted options, marking a significant step in its capital management strategy.

Legacy Minerals retains 100% ownership of the Bauloora Gold-Silver Project after Newmont's withdrawal and secures the high-grade Mt Terrible Gold-Copper Project in NSW, positioning itself strongly amid record precious metals prices.

Eclipse Metals announces plans for a NASDAQ dual listing to boost its rare earth elements strategy and tap into North American capital markets, while maintaining its ASX presence.

Cann Group Limited has extended the expiry of its National Australia Bank debt facilities by one year to October 2025, maintaining current terms while exploring long-term refinancing options.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

29Metals maintains steady copper output at Golden Grove despite seismic disruptions to zinc production, while progressing key growth projects and regulatory steps toward Capricorn Copper’s restart.

Sheffield Resources achieved a record quarterly concentrate production at its Thunderbird mine but faces subdued zircon sales due to challenging market conditions in China, withholding December quarter guidance.

Warriedar Resources Limited has increased the consideration offered to shareholders and optionholders in its proposed acquisition by Capricorn Metals Limited. An independent expert has affirmed the revised terms as fair and reasonable, with the Warriedar board unanimously recommending approval.

MFF Capital Investments Limited has confirmed a fully franked dividend of AUD 0.09 per share for the six months ending June 2025, alongside updated Dividend Reinvestment and Bonus Security Plan prices.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.